Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 19, 2016

R-Biopharm signs agreement with HMNC Brain Health to develop complementary diagnostic test

R-Biopharm has entered into a collaboration agreement with HMNC Brain Health for complementary diagnostics.

R-Biopharm has entered into a collaboration agreement with HMNC Brain Health for complementary diagnostics.

As part of the agreement R-Biopharm AG will develop an in-vitro polymerase chain reaction (PCR) based genetic test.

The aim is to identify ABCB1 gene variants in patients who are treated with antidepressants in order to optimise the efficacy of depression therapy.

"A laboratory test that supports the physician in his treatment decision to choose the best drug and the appropriate dose for the individual patient represents a major improvement in antidepressant treatment."

This collaboration includes the development, regulatory approval, manufacturing and commercialisation of the ABCB1 test.

R-Biopharm AG companion diagnostics Dr. Frank Apostel said: "Complementary diagnostics play a central role in delivering tools that help identifying those individuals who are most likely to benefit from specific treatments.

"We are delighted about this agreement as it expands our service in the field of personalised healthcare.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

"Our goal is to help patients and their physicians to determine the best treatment option available."

HMNC Brain Health CEO Professor Florian Holsboer said: "A laboratory test that supports the physician in his treatment decision to choose the best drug and the appropriate dose for the individual patient represents a major improvement in antidepressant treatment.

"To develop the ABCB1 test together with R-Biopharm is encouraging and an important step to achieve our ambitious goal even faster."

Complementary diagnostics are increasing in demand as personalised medicine offers a way to bolster patient care and reduce health care costs by matching specific therapies to individuals most likely to benefit from them, as all patients do not respond in the same way.

Financial terms of the agreement have not been not disclosed.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU